Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome

BMC Endocrine Disorders

Table 4 Multiple regression analysis on maximum tumor diameter and serum potassium concentration with respect to patients in the PA, SCS, and PASCS groups who had a unilateral adrenal tumor (n = 65)

	Crude model			Adjusted model^a
	Difference	(95% CI)	P value	Difference	(95% CI)	P value
MTD, cm
PASCS (n = 12^b)	Reference			Reference
PA (n = 41^c)	−1.24	(– 1.70 to −0.78)	< 0.001	– 1.19	(– 1.66 to − 0.72)	< 0.001
SCS (n = 12)	−0.04	(– 0.58 to 0.57)	NS	– 0.01	(– 0.55 to 0.54)	NS
Serum potassium concentration, mEq/L
PASCS (n = 12^b)	Reference			Reference
PA (n = 41^c)	0.23	(−0.23 to 0.69)	NS	0.24	(−0.25 to 0.72)	NS
SCS (n = 12)	0.96	(0.38 to 1.53)	< 0.005	0.97	(0.38 to 1.54)	< 0.005

^aConsists of 65patients who had a unilateral adrenal tumor (41, 12, and 12 patients with PA, SCS, and PASCS, respectively). All the models were adjusted for age, sex, and BMI at the time of diagnosis
^bThe numbers of patients who remained after the exclusion of 2 patients who had bilateral tumors and who missed the maximum tumor diameter
^cThe numbers of patients who remained after the exclusion of the following patients who missed the maximum tumor diameter: 1 patient who had a unilateral adrenal tumor and 3 patients who had bilateral adrenal tumors
PA primary aldosteronism, SCS subclinical Cushing’s syndrome, NS not significant, PASCS primary aldosteronism plus subclinical Cushing’s syndrome, CI confidence interval, MTD maximum tumor diameter